---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-129488"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T09:36:02.751452+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B

## Summary
- €1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.
- Net proceeds fund tender offer for up to $2.25B (upsized from $2B) and repay other outstanding debt.
- Notes are senior unsecured obligations guaranteed by Teva; customary covenants and events of default.
- Issuance made under Teva's existing shelf registration statement filed February 2025.

## SEC filing metadata
- accession: 0001193125-25-129488
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/0001193125-25-129488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/d918164d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-129488
- JSON: https://secwatch.observer/filing/0001193125-25-129488.json
- Plain text: https://secwatch.observer/filing/0001193125-25-129488.txt

## Key facts
- Debt Financings
  TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of €1,000,000,000 with The Bank of New York Mellon, as trustee at 4.125% maturing June 1, 2031.
  - Instrument: senior notes
  - Principal: €1,000,000,000
  - Counterparty: The Bank of New York Mellon, as trustee
  - Rate: 4.125%
  - Maturity: June 1, 2031
  - Event: incurrence
  source text: On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/0001193125-25-129488-index.htm
- Debt Financings
  TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of $500,000,000 with The Bank of New York Mellon, as trustee at 6.000% maturing December 1, 2032.
  - Instrument: senior notes
  - Principal: $500,000,000
  - Counterparty: The Bank of New York Mellon, as trustee
  - Rate: 6.000%
  - Maturity: December 1, 2032
  - Event: incurrence
  source text: On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/0001193125-25-129488-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.